Ifosfamide

Marginal Zone Lymphoma

University of MiamiPhase 2Dormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE University of Miami	Phase 2	BBB
Orelabrutinib Henan Cancer Hospital	Phase 4	BBB
Fludarabine Paolo Caimi, MD	Phase 2	BBB
FILGRASTIM Fred Hutchinson Cancer Center	Phase 2	BBB
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2	BBB

View all 50 →

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant

BBB

Indicative ·

76 / 100

primary mediastinal large B-cell lymphomaDormant

BBB

Indicative ·

76 / 100

Hodgkins lymphomaDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.